Peaks in plasma plasminogen activator inhibitor‐1 concentration may explain thrombotic events in cases of pancreatic carcinoma

Cancer

Volumn 69, Issue 12, 1992, Pages 2884-2887

  Andrén‐Sandberg, Åke ^a   Lecander, Ingegerd ^a   Martinsson, Gunilla ^a   Åstedt, Birger ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DEEP VEIN THROMBOSIS; FIBRINOLYSIS; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; THROMBOSIS;

HUMAN; PANCREATIC NEOPLASMS; PLASMINOGEN INACTIVATORS; SUPPORT, NON-U.S. GOV'T; THROMBOSIS;

EID: 0026631647     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19920615)69:12<2884::AID-CNCR2820691204>3.0.CO;2-S     Document Type: Article

References (26)

1. Phlegmasia alba dolens
2. Hemostasis in malignancy
3. Thromboembolism in cancer patients
4. Haemostasis and cancer
5. Tumors, mucus production, and hypercoagulability
6. Thrombophlebitis migrans and carcinoma of body and tail of pancreas
7. Das Pankreaskarzinom
8. Pancreatic cancer: The greatest oncological challenge
9. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor
10. A novel fast inhibitor to tissue plasminogen activator in plasma, which may be of great pathophysiological significance
11. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
12. Deficient t‐PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis
13. Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures
14. Specific plasminogen activator inhibitor of placental type PAI 2 occurring in amniotic fluid and cord blood
15. Occurrence of a specific plasminogen activator inhibitor of placental type, PAI‐2, in men and non‐pregnant women
16. Clinical, pathologic and therapeutic aspects of carcinoma of the pancreas
17. Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor and an inhibitor‐trypsin compound
18. In vitroand in vivostudies with Trasylol, an anticoagulant and a fibrinolytic inhibitor
19. Inhibition of human trypsin, plasmin, and thrombin by naturally occurring inhibitors of pro‐teolytic enzymes
20. Identification of tissue factor in two human pancreatic cancer cell lines
21. Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour
22. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombois
23. Detection and partial characterization of an inhibitor of plasmhogen activator in human platelets
24. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia
25. Development of venous occlusions in mice transgenic for plasminogen activator inhibitor‐1 gene